Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular markers guide diagnosis and treatment in Philadelphia chromosome-negative myeloproliferative disorders (Review).

Oncology reports - 1 Mar 2010

Vladareanu Ana Maria, Müller-Tidow Carsten, Bumbea Horia, Radesi Sinziana

Abstract excerpt

The Philadelphia negative chronic myeloproliferative neoplasms are hematological disorders with several diagnostic challenges. Due to recent molecular findings, the WHO classification of Tumors of Hematopoietic and Lymphoid Tissue 2008 reorganized the field of chronic myeloproliferative diseases....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to GPI-Linked Proteins
Share to Isoantigens
Share to Myeloproliferative Disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Philadelphia Chromosome

Share to Receptor, Fibroblast Growth Factor, Type 1

Share to Receptor, Platelet-Derived Growth Factor alpha

Share to Receptor, Platelet-Derived Growth Factor beta

Share to Receptors, Thrombopoietin

Source

Identifiers

PMID: 20126996
DOI: 10.3892/or_00000674

Genes

FGFR1
PDGFRA
PDGFRB

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20126996-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular markers guide diagnosis and treatment in Philadelphia chromosome-negative myeloproliferative disorders (Review).PMID 20126996Read ↗

Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.Semantic proximity Read ↗

Myeloproliferative neoplasms: updates on molecular pathophysiology, diagnosis and treatment strategies.Semantic proximity Read ↗

Genetic basis of MPN: Beyond JAK2-V617F.Semantic proximity Read ↗

The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markersSemantic proximity Read ↗

Current Concepts of Pathogenesis and Treatment of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.Semantic proximity Read ↗

Guidelines for the management of myeloproliferative neoplasms.Semantic proximity Read ↗

Molecular diagnostic criteria of myeloproliferative neoplasms.Semantic proximity Read ↗

[CURRENT CRITERIA FOR THE DIAGNOSIS OF MYELOPROLIFERATIVE NEOPLASMS - WHAT IS IMPORTANT TO KNOW?]Semantic proximity Read ↗

Cytogenetic and molecular aspects of Philadelphia negative chronic myeloproliferative disorders: clinical implications.Semantic proximity Read ↗

Molecular profiling in MPN: who should have it and why?Semantic proximity Read ↗

Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics.Semantic proximity Read ↗

Cytological Diagnosis of Classic Myeloproliferative Neoplasms at the Age of Molecular Biology.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.